| 31.3181 -0.947 (-2.93%) | 04-21 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 38.12 | 1-year : | 44.53 |
| Resists | First : | 32.64 | Second : | 38.12 |
| Pivot price | 31.76  |
|||
| Supports | First : | 30.87 | Second : | 29.79 |
| MAs | MA(5) : | 31.99 |
MA(20) : | 31.37 |
| MA(100) : | 33.52 |
MA(250) : | 29.1 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 71.1 |
D(3) : | 83.1 |
| RSI | RSI(14): 44.5 |
|||
| 52-week | High : | 37.15 | Low : | 22.8 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ OZEM ] has closed above bottom band by 16.0%. Bollinger Bands are 57.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 31.55 - 31.74 | 31.74 - 31.88 |
| Low: | 30.73 - 30.98 | 30.98 - 31.16 |
| Close: | 30.99 - 31.36 | 31.36 - 31.61 |
Roundhill believes that weight loss drugs, including GLP-1 agonists, represent one of the most revolutionary advancements in the global pharmaceuticals industry. The Roundhill GLP-1 & Weight Loss ETF (“OZEM”) is the world’s first GLP-1 ETF. OZEM is an actively-managed ETF.
Fri, 17 Apr 2026
3 Ways to Invest in the Growing GLP-1 Weight Loss Market - MarketBeat
Fri, 13 Feb 2026
How to Invest in GLP-1 Stocks in 2026 - The Motley Fool
Fri, 30 Jan 2026
OZEM Vs. THNR: Which Is The Better ETF In The GLP-1 And Weight Loss Space? - Seeking Alpha
Tue, 27 Jan 2026
EXCLUSIVE: Trump 'Amplified' Several Investing Themes – ETF CEO Picks 3 Sectors Benefitting The Most - Benzinga
Mon, 12 Jan 2026
New Year, New Strategy: Navigating Weight Loss ETFs - ETF Trends
Wed, 11 Jun 2025
Weight-Loss Drug ETFs Generate Skinnier Returns Than Expected - The Daily Upside
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Financial Services
|
|
|
Industry:
Asset Management
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|